THINKMD receives $2.3 Million grant from Gates Foundation and a Pfizer Foundation Grant

A two-year, $2.3 million program-related investment grant has been awarded to VTTA member THINKMD by the Bill & Melinda Gates Foundation for the development of a globally scalable standardized Fast Healthcare Interoperability Resources (FHIR)-based clinical Application Programming Interface (API).

The grant will also support data analytics and machine learning modelling for THINKMD’s clinical assessments and UX/UI components, as well as field-based studies to test scaling models.  This will allow for exploration of the multitude of ways that THINKMD’s clinical intelligence API can be globally distributed in all economic markets.

For a third year in a row, The Pfizer Foundation has awarded a grant to THINKMD to improve its clinical algorithms and data analytics to assist frontline health workers to accurately identify acute febrile illnesses (AFIs), leading to better health outcomes. 

 THINKMD has already begun this AFI work, having improved its malaria risk assessment in two rounds of machine learning analysis. In this third year of The Pfizer Foundation’s Global Health Innovation Grant (GHIG), confirmatory diagnostic tests in combination with THINKMD’s risk assessment for dengue, urinary tract infection, and other illnesses will enable THINKMD to continue to hone risk assessments associated with fever (febrile illness). Ultimately, THINKMD will create enough risk profiles using individual symptomology and confirmatory tests to improve clinical risk assessments for febrile illnesses.